About your Search

20130106
20130114
Search Results 0 to 27 of about 28 (some duplicates have been removed)
. tonight, jim's got two exclusives. the ceos of nps pharma and exact sciences just ahead. >>> and later, king of the hill. they're the two top performers in the dow last year. but 2013 isn't big enough for both of them. with the big mortgage settlement behind them, could bank of america deposit returns for you this year, or should the housing rebound keep home depot in your sights? cramer decides. all coming up on "mad money." >>> don't miss a second of "mad money." follow @jimcramer on twitter. send jim an e-mail at jimcramercnbc.com or call 1-800-743-cnbc. miss something? head to madmoney.cnbc.com. with the spark cash card from capital one, sven gets great rewards for his small business! how does this thing work? oh, i like it! [ garth ] sven's small business earns 2% cash back on every purchase, every day! woo-hoo!!! so that's ten security gators, right? put them on my spark card! why settle for less? testing hot tar... great businesses deserve great rewards! [ male announcer ] the spark business card from capital one. choose unlimited rewards with 2% cash back or double miles on ev
performance and that science magazine named you one of the best pharmaceutical companies in the world. >> we are lucky. my partner since we opened the labs nearly 25 years ago, actually we started the company. today is our birthday. 25 years ago today we actually signed the first papers that started the company. but when we opened the labs in 1989, my partner, we believed that the key to the business was to do good science and then get individual scientists and treat them well and let them run and they would get across the finish line like they have. i thought the sales were amazing. did they expect more because one of your competitors was caught up in a pharmacy compounding problem? is that what people expected because of the problem with your competitor? >> yeah, it is hard to know what drives people exactly expect and why they expect it. but there was a problem with compounding pharmacies. people had fungal meningitis and died. but that put a question mark around a lot of drugs and people thought that the market leader actually, this drug avacin which is used off label but made by compoun
beeps] >> dr. mintz considers himself a pioneer in this gray area of law and science, and there are plenty of patients eager to follow the trail he's blazing. the ones we talked to in las vegas, all eager to remain young and vital, consider this a lifestyle choice, and they're prepared to roll the dice. you aren't concerned that five years from now, somebody might do a study and find out that this regimen accelerates the growth of cancer cells or causes diabetes? >> well, that's happened with prescriptive drugs. i mean, has it not? so this is any-- in any field you're doing this. they're taken drugs off the market because of this. >> so you'd rather feel better now while you're living your life than worry about the possibly downside 10 or 15 years from now? >> you could get killed on the interstate tomorrow. i mean, my goodness. i mean, it's-- you have to weigh risks and rewards. you do that every day in life. you do it when you get up in the morning. >> are you sure, are you absolutely positive, absent any scientific studies, that the treatments that you're giving no
and you can't have those unless you're involved early in science. we developed models where we are integrated into the ecosystems around the world. i was at stanford this morning where the biggest life sciences employer in boston, we have a strong hub in china and in europe. and we are really trying to develop a collaborative open innovative concept. what we put in has to have a strong proof of concept. on vaccines, on drugs that have a clear benefit over existing therapies. because the bar just gets higher and higher from reimbursement authorities every year. >> sure. and does that include transactions -- more transactions in terms of mna? you know, some of your growth has come through acquisitions. going forward in the next three years, does that growth continue to come through acquisitions or organic? >> i think it's going to be more organic. i'll tell you. in our industry, everybody's got a lot of cash. everybody is interested in growing inorganically. it's tough to find deals that have value. because sanofi now grows we have less than 3% subject to small molecule patents e
has been to china many times knows his markets and political science has told us china was way too restrictive in the monetary policy, that somehow the communist party got caught up on worrying about inflation, not worrying about growth. come on, malice, be like mal for heaven sake. i think they're still going with the techs, though. that's over. klaus is confident that when the dpovt unveils the plan for growth in february, they're going to dazzle, from a disappointing 8% to a stunning 11%. there's plenty to like if china gets ho the t in here and takin all its clothes, that's ray lewis. the chinese are addicted to coal. and we know electric uses have gotten stronger and stronger as the year's gone on. got that data. although joy's up about 10% in two weeks. you can look at truck manufacturers as the chinese are back with a vengeance. but i don't know, i don't want to outthink this. the best way to play china is china, specifically the etf for the biggest chinese stocks i've steered you away from owning individual stocks except for brief flirtation with baydu. nevertheless, call m
off. gilead sciences moving up. says today's update keeps gilead in the race which he says is an $18 billion market opportunity. ls elsewhere we're seeing a bright spot in the biotech space for celgene. also activity to keep note of, athenahealth in the mobile health care space. epocrates added a 2% premium. it's a small cap, but that stock is moving sharply higher today. look at illumina. that's not what's moving the stock. here's what is. telling the newspaper over the weekend that illumina is definitely off the table based on those comments. there is speculation that roche may not further pursue an illumina deal. that's what's weighing on shares of illumina today. >> thank you so much. >>> coming up, we'll talk with the head of one of the biggest today. the ceo of snofi chris viehbacher. >> there's a lot of flu going around. it's a bad one. minutes before the bell, look where the dow sits now. dow at 13,387 and change. >> google executive chairman eric schmidt arrived today in north korea. not a popular move with the white house. but google stock is popular with investors. that st
is a great company, we've been this business for 32 years. we have tremendous science based products that are high in health and safety and a tremendous business opportunity. we're proud of where we are today and confident about our future. >> after the herbalife meeting ends, michael john so thson wil appear on skauk squawk on the treat. must see tv. this story has legs. >> as an investment story, i can make an argument that perhaps we're overdoing it a bit. but as a story, come on. the fact as of yesterday this new plot twist with dan taking on where he thought his friend, referring to him only, though, as the short seller. i thought that was a little hostile in his letter. just adds another layer of intrigue. and significant money at stake for both hedge funds. >> and herb greenberg has been on this for a very long time. michael johnson has come on my show at mod money. but he has a documentary that's fascinating. in terms of timely, i've never seen anything like it. >> it has been in the works for months. so check it out if you haven't already. called selling the dream. but in te
, and he'll set money aside from his first day of work to his last, which isn't rocket science. it's just common sense. from td ameritrade. it's just common sense. living with moderate to semeans living with pain.is it could also mean living with joint damage. help relieve the pain and stop the damage with humira, adalimumab. for many adults with moderate to severe ra, humira is clinically proven to help relieve pain and stop joint damage. so you can treat more than just the pain. humira can lower your ability to fight infections, including tuberculosis. serious, sometimes fatal events, such as infections, lymphoma, or other types of cancer, have happened. blood, liver and nervous system problems, serious allergic reactions, and new or worsening heart failure have occurred. before starting humira, your doctor should test you for tb. ask your doctor if you live in or have been to a region where certain fungal infections are common. tell your doctor if you have had tb, hepatitis b, are prone to infections or have symptoms such as fever, fatigue, cough, or sores. you should not start humira
of work to his last, which isn't rocket science. it's just common sense. from td ameritrade. ♪ ♪ ♪ [ male announcer ] don't just reject convention. drown it out. introducing the all-new 2013 lexus ls f sport. an entirely new pursuit. >>> take a look at shares of boeing. they are up by about 3% move. moving up after selling off monday and tuesday. coming after several problems with the company's dream liner aircraft. but boeing doing a little bit of push back today aep phil has the story. hi, phil. >> hi, tyler. boeing just wrapped up a conference call with reporters updating where they believe the 787 is in terms of reliability. two pieces of news. the first one being that in terms of reliability after 15 airplanes in service, the dream plane is where the 787 was. rebuilt of taking off and landing on time. other piece of news has to do the lithium ion batteries on board. here is what the chief of safety has it say about use of these batteries. >> we have over a million hours of safe operation of these battery cell in flight. so i continue to be very confident in the battery technology and
, which isn't rocket science. it's just common sense. from td ameritrade. it's just common sense. you know it can be hard to lbreathe, and how that feels.e, copd includes chronic bronchitis and emphysema. spiriva helps control my copd symptoms by keeping my airways open for 24 hours. plus, it reduces copd flare-ups. spiriva is the only once-daily inhaled copd maintenance treatment that does both. spiriva handihaler tiotropium bromide inhalation powder does not replace fast-acting inhalers for sudden symptoms. tell your doctor if you have kidney problems, glaucoma, trouble urinating, or an enlarged prostate. these may worsen with spiriva. discuss all medicines you take, even eye drops. stop taking spiriva and seek immediate medical help if your breathing suddenly worsens, your throat or tongue swells, you get hives, vision changes or eye pain, or problems passing urine. other side effects include dry mouth and constipation. nothing can reverse copd. spiriva helps me breathe better. (blowing sound) ask your doctor about spiriva. >>> welcome back to "power lunch." here we have backed off rath
things, like each other, which isn't rocket science. it's just common sense. from td ameritrade. >>> welcome back to the floor of the new york stock exchange and time for the friday edition of the closing countdown. wells fargo kicking off the big bank earnings today. earnings better than expected. loan growth though really concerned the street and then how much money the bank actually makes off of those
of work to his last, which isn't rocket science. it's just common sense. from td ameritrade. it's just common sense. we asked total strangers to watch it for us. thank you so much. i appreciate it. i'll be right back. they didn't take a dime. how much in fees does your bank take to watch your money? if your bank takes more money than a stranger, you need an ally. ally bank. your money needs an ally. ♪ [ male announcer ] don't just reject convention. drown it out. introducing the all-new 2013 lexus ls f sport. an entirely new pursuit. office superstore ink retailer in america. now get $6 back in staples rewards for every ink cartridge you recycle when you spend $50 on hp ink. staples. that was easy. >>> what happens when you combine two game-changing ideas to one company. you have a stock like athena health, one that's run up 57% in the last 12 months. athena provides software platforms for electronic medical records and for helping doctors collect their bills from patients and insurance companies. they're trying to modernize the doctors office along the lines of a company like cerna,
straightforward guidance and be able to focus on other things, like each other, which isn't rocket science. it's just common sense. from td ameritrade. >>> welcome back to the "closing bell." a number of individual stock stories today but certainly you have to start with dow component boeing. even more problems now emerging with the 787 dreamliner. that stock trading a tremendous volume today and also the stock is down for a second straight day, 2.75%. another stock people are watching quite closely is yum brands because of its exposure in china and that all of that means in the big picture of not only what the company is doing but what'spe
things, like each other, which isn't rocket science. it's just common sense. from td ameritrade. >>> all right. welcome back to the floor of the new york stock exchange. time now for the closing countdown as we approach the close. pretty good day on wall street. schactman and i were just talking about this herbalife story. stock down 2%. ceo speaking on cnbc exclusively right there and that's where the stock fell. an interesting story we continue to follow. tiffany really set the tone early on for that stock. holiday sales at the low end of expectations. outlook disappointing as well raising questions about what the high-end retailers are doing. a number to watch. stock down nearly 5 has. apple, tim cook meeting with china mobile. is he going to do that deal in the market would certainly love it if he did and amazon named deutsche bank's favorite large-cap e-commerce name.
him, and he'll set money aside from his first day of work to his last, which isn't rocket science. it's just common sense. from td ameritrade. >>> welcome back to "power lunch." we're looking at sarasota of occidental petroleum, the energy company up over 2.5%. the company saying it's cost-cutting man, an effort to cut $300 million in costs is on track. it should be visible in the fourth quarter and even more visible in the first quarter. investors like that news. stock up 2.55%. tyler, back to you. >> mary, thank you very much. target has announced a major move with implications for retail across the board of the company promising to match online retailer's prices year-round. there you see shares at $60.70 down half a buck. >> tart may be packing away holiday decorations but keeping price match around. the retailer will continue to match online prices, in addition to three-year running price match program many analysts not entirely surprised and think others will have to follow. susquehanna says the effort cannot be a holiday phenomenon. if you're going to build traction with your st
things, like each other, which isn't rocket science. it's just common sense. from td ameritrade. i am probably going to the gas station about once a month. last time i was at a gas station was about...i would say... two months ago. i very rarely put gas in my chevy volt. i go to the gas station such a small amount that i forget how to put gas in my car. [ male announcer ] and it's not just these owners giving the volt high praise. volt received the j.d. power and associates appeal award two years in a row. ♪ >>> and welcome back, as we await the presumed nomination of jack lew to proceed timothy geithner as treasury secretary. who might replace jack lew as chief of staff at white house? >> there is. two main candidates talked about. one is ron claim, former chief of staff to vice president biden. he also served in the clinton administration. very experienced washington hand. but the lead candidate, i'm told is dennis mcdona. long time obama aid. he would fit the practice, the pattern that president established of picking people close to him for key jobs. like jack lew, he is a no-dr
's in aeronautical science, correct? >> i do. >> how does that inform your view of what this problem may be? if in fact there is a problem. >> well, you know, a phil pointed out, i would expect that they would come out and say what they said. we've never doubted that the airplane -- the airplane is safe, and ultimately boeing will get through this. our concerns, and why we went to a hold a few days ago, is this very fact, that the faa is in scrutinizing your plane. it's akin to having a tax audit. it likely goes well, but you just don't like to have the irs snooping around on things that have already been put to bed. >> the boeing executive who spoke this morning, the problem he does not believe is related to outsourcing. had that occurred to you, that that could be a problem? or a factor in this complication? >> well, it was interesting. you know, i think we're in the phase of unknown unknowns, so boeing, we don't know what we don't know right now. so i know they're saying that. but we have the faa all over the airplane, the ntsb all over the airplane. i think the risk for the -- i see two
. that's actually one of the key things in biotech. the science is so good, that if you have the capital, and the staying power, over time you tend to win. and so when capital is available, biotech innovation continues to expand. in our case because we have these recurring cash flows and strong financial base, we think we can keep growing. so for us today, we'll be talking about two things about the company. the commercial portfolio, the approved products already that are driving our growth. and this pipeline that you're referring to, of our medicines with schizophrenia, addiction and depression. >> well, good luck today. and at the conference, mr. pops. appreciate your time. >> thank you very much. >> richard pops, chairman and ceo of alkermes. >> we want to take a check on shares of netflix, trading above $100 a share for the first time in eight months. april 23rd to be exact. take a look at this, up 5%. this comes on the heels of a deal with time warner to carry previous seasons of some of the popular shows that are produced by time warner tv. so that another content deal in the quive
to focus on other things, like each other, which isn't rocket science. it's just common sense. from td ameritrade. >>> welcome back, everyone. shares of vodafone this morning rose in europe after verizon ceo said that it would be, quote, feasible to buy out vodafone's 45% stake in verizon wireless. some analysts say that a deal could be worth as much as $100 billion. however, there's a report this morning saying a direct purchase of the vodafone stake of verizon wireless is unlikely because of tax consequences for vodafone. >> all right. real quick m&a guy having covered that, about ten years, we've all been waiting for that deal to happen. never going to happen. >> let's get to our guest host senator ron johnson is a member of the commerce and budget committee, and john allison is a former bb&t ceo. now the new president of the cato institute. senator, you know what the inner workings are going to look like for the debt ceiling. what are your colleagues saying at this point? we've got -- we've got the other side saying it's not going to be about spending cuts. we need another whatever
tremendous science-based products that are very high in health and safety and efficacy and we've got a tremendous business opportunity and we're proud of where we are today and confident about our future. >> okay, des, let's talk about the pyramid scheme thesis for a second. first, of your distributors, every year, new distributors join the forces of herbalife, and invariably the argument is made that a large majority of those distributors at the end of year one don't become the millionaires or even making $100,000 or $50,000 or $10,000 that they see in the ads but ultimately that they lose money. pis that true? >> absolutely not. here's one of the fallacies we're hearing from pershing square. what the research shows is the majority of our distributors become distributors because of their affinity with the product and they want to receive a discount. so essentially they're almost like members, club members just like in costco. that's the reality. most of the distributors come for that product discount. of those distributors who come for business opportunity, absolutely they make mone
guidance and be able to focus on other things, like each other, which isn't rocket science. it's just common sense. from td ameritrade. that's a good thing, but it doesn't cover everything. only about 80% of your part b medical expenses. the rest is up to you. so consider an aarp medicare supplement insurance plan, insured by unitedhealthcare insurance company. like all standardized medicare supplement plans, they help save you up to thousands in out-of-pocket costs. call today to request a free decision guide. with these types of plans, you'll be able to visit any doctor or hospital that accepts medicare patients... plus, there are no networks, and you'll never need a referral to see a specialist. join the millions who have already enrolled in the only medicare supplement insurance plans endorsed by aarp... and provided by unitedhealthcare insurance company, which has over 30 years of experience behind it. with all the good years ahead, look for the experience and commitment to go the distance with you. call now to request your free decision guide. >>> welcome back to "squawk box." a
guidance. celgene and gillead sciences is hitting an all-time high. they're blaming infighting over the fiscal cliff for an industry slowdown of the end of last year. the global business travel association says spending by u.s. companies rising 1.6% last year. that's worrying, because companies invest in business travel when they want to drive their top line growth. and that effect may show up later down 9 line. the coo said a timely resolution to the debt ceiling, with that spending, could reaccelerate with the full year pushing up to 4.6%. >> largely, business travels has been in a holding pattern, has been in the latter half of 2012. and most likely will be for the first half of this year. but if we start to see some more of that confidence resume, companies will, cfos w begin to release the budgets that they've planned for business travel to really start pushing the pedal on the gas to grow the economy again. >> moving on here, as the streaming wars heat up between amazon and netflix, red box offering a monthly rental plan under the name red box instant. we're joined now from ce
Search Results 0 to 27 of about 28 (some duplicates have been removed)